Health Care • Biotechnology: Pharmaceutical Preparations
$39.18 ▲ +0.63
(+1.63%)
MKT CAP: $1.34B • VOL: 490.4K
52W L $33 52W H $109
ROARABLE / RQD
E • 21/100
PIOTROSKI
2 / 9
NKTR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $55.2M | $98.4M | $90.1M |
| YoY Revenue Growth % | -43.9% | +9.2% | — |
| Gross Profit | $55.2M | $67.7M | — |
| Gross Margin % | 98.0% | 68.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$140.1M | -$105.2M | -$263.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$164.0M | -$119.0M | -$276.0M |
| EBITDA (Normalized) | -$140.0M | -$104.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$208.5M | -$175.7M | -$192.6M |
| Capital Expenditures (CapEx) | $171.0K | $1.5M | — |
| Free Cash Flow (FCF) | -$208.7M | -$177.2M | -$192.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $15.1M | $44.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $89.8M | $60.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NKTR.